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Hypoxia-inducible factor 1-alphaA prominent role for mitochondrial genes and metabolism has been recently characterized in oncocytic
transformation of cancer cells. From mitochondrial ultrastructure alterations to respiratory complexes
disruption and mutations within mitochondrial genes, oncocytic tumors present with a plethora of features
that have helped understand the role that these organelles and their fundamental metabolic functions may
play in cancer development. The history of this under-diagnosed subset of tumors and the bioenergetic
implications of their mitochondrial derangement are discussed in this review along with the opportunities
that oncocytic tumors offer to draw general conclusions on the involvement of mitochondria in cancer. This
article is part of a Special Issue entitled: Bioenergetics of Cancer.ergetics of Cancer.
Ostetriche e Pediatriche, U.O.
arenti 9, 40138, Bologna, Italy.
l rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction—clinical, histopathological and ultrastructural
features of oncocytic tumors
Oncocytic neoplasms are tumors composed of cells characterized by
anaberrant amountofmitochondria that is responsible for their “swollen”
(i.e. oncocytic) appearance [1]. They are of epithelial origin and mainly
occur in endocrine and exocrine tissues such as the thyroid, parathyroids,
kidney, salivary and pituitary gland (for a review see [1]). Nevertheless
oncocytic transformation has been seldomobserved in organs such as the
lungs [2], endometrium [3], colorectum [4–6], liver [7,8], breast [9–11],
ocular adnexa (for a review see [12,13]) and even in melanocytic nevi
[14]. Both oncocytic adenomas and carcinomas have been reported,
particularly in the thyroid, where they have been most frequently
described. Unlike in other organs, thyroid tumors are deﬁned as oncocytic
when at least 75% of neoplastic cells display the typical mitochondrial
hyperplasia. Kidney and salivary gland neoplasms (Warthin tumor and
parotid oncocytoma) require instead stricter criteria in order to be
classiﬁed as oncocytic and hence represent a more homogeneous
neoplastic tissue than in the thyroid [1]. Heterogeneous tumors have
been described in which oncocytic foci and/or mitochondria-rich cells
have been reported, such as in pituitary adenoma or breast cancer [15–17]. The majority of oncocytic neoplasms is considered to be benign and
displays low invasiveness. Prognosis of kidney oncocytoma, Warthin
tumor andoncocytic pituitary adenoma is in fact usually favourable. In the
thyroid the best indicator for prognosis remains the degree of
differentiation of neoplastic cells which deﬁnes adenoma or carcinoma,
regardless of the occurrence of oncocytic transformation. Hence, the
conventional criteria of vascular and capsular invasion may be applied to
predictmalignant behaviour [1], and the reported increase inmortality of
oncocytic compared to non-oncocytic carcinomamaybedue to a reduced
competence in iodine-131 uptake [18] rather than to the occurrence of a
speciﬁc oncocytic phenotype. This observation is in agreement with the
ﬁndings that oncocytic metaplasia is not uncommon in non-neoplastic
epithelia with high metabolic activity and may be associated with
inﬂammatory conditions such as Hashimoto's thyroiditis [1].
Diagnosis of oncocytic tumors is generally carried out on tissue
sections since cytoplasmic eosin staining is particularly intense
(hence the term of oxyphilic or eosinophilic tumors). However,
since such staining is not always speciﬁc, antibodies against subunits
of the respiratory chain have been introduced in diagnostic proce-
dures as markers of mitochondrial hyperplasia [1]. Nonetheless, the
most striking feature of oncocytic tumors is appreciated through
ultrastructural analysis, which displays cells packed with enlarged
globular or ovate mitochondria with a stack of lamelliform, tubular or
ﬂat cristae and occupying up to 60% of the cytoplasm [1,19,20]. The
heterogeneity in mitochondrial morphology observed in oncocytes is
suggestive of a functional, along with a structural alteration of these
organelles. Nevertheless, the evidence of a dysfunction of
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attempt to verify the hypothesis that the mitochondrial hyperplasia
typical of these cells may be due to a compensatory effect.
2. Why do oncocytic tumors present with mitochondrial
hyperplasia?—The compensatory effect hypothesis
The presence of morphologically altered mitochondria in oncocytic
tumors has led to hypothesize that a compensatory effect may be
triggered in presence of a retrograde signalling from the organelles to
the nucleus. Such signalling has been widely investigated and several
mechanisms have been described in which a mitochondrial stress
response is activated upon the occurrence of a variety of stimuli, i.e. loss
of mitochondrial function caused by collapse of electrochemical
potential, impaired respiratory chain activity or by the accumulation
of unfolded proteins in the organelle (for a review see [21]) and a
decrease in oxygen tension (at least in the initial tumor stages before
neovascularization). A metabolic stress may be envisioned in tumor
cells, which induces a nuclear response leading to the activation of
mitochondrial biogenesis pathways with the intent to restore a
defective respiration. In the attempt to reject the compensatory effect
hypothesis, Ebner et al. measured the activity of the four respiratory
complexes and mitochondrial DNA (mtDNA) copy number in nine
oncocytic thyroid tumors, showing an increase of all complexes activity
and of mtDNA copies that did not display molecular alterations upon
restriction pattern analysis [22]. It has tobeunderlined that few samples
were analyzed by Ebner et al., and that thyroid oncocytic tumors often
display a heterogenous composition that may mask a speciﬁc
phenotype. In fact, the compensatory effect hypothesis has later been
re-proposed and reinforced. Several studies have investigated the
increase in mitochondrial biogenesis in oncocytic tumors as well as in
the only actually existing model of oncocytic cancer, the XTC.UC1 cell
line. The authors reported a defective mitochondrial ATP synthesis and
overexpression of uncoupling proteins such as UCP2 in thyroid
oncocytic tumors [23–25], which may explain the observed increase
in the expression of the biogenesis regulator PGC-1-related coactivator
(PRC) [26] as well as that of a large number of mitochondrial- and
nuclear-encoded mitochondrial proteins [27]. The group of Savagner,
therefore, concluded that the defective ATP synthesis may explain the
mitochondrial hyperplasia and may hence justify the compensatory
effect and this may be due to an oxidative phosphorylation coupling
defect whose causes, though, remain to date unknown [24]. Noticeably,
these mechanisms were investigated only in thyroid and may not be
necessarily involved in other types of oncocytic tumors. Tissue
speciﬁcity, tumor stage and homogeneity and the presence of an
inﬂammatory inﬁltrate may affect both the metabolic status of
developing tumor cells and gene expression. Before a coupling defect
is deﬁned as themain responsible of oncocytic transformation, analyses
should therefore be performed in other oncocytomas. Overall, different
studies conﬁrm the up-regulation of mitochondrial proteins both in
thyroid and kidney oncocytomas, despite the clinical and phenotypical
differences of the two types of neoplasms [27–29]. Particularly, the
increase both in protein content and activity of respiratory complexes II,
III, IV and V as well as of citrate synthase, a marker of mitochondrial
mass, seems to be a common feature of kidney oncocytomas in
correlation with their benign behaviour [30]. In apparent contrast,
deﬁciency of cytochrome c oxidase has been observed both in terms of
activity and of subunits histochemical staining patterns, in oncocytes of
bothnormal andhyperfunctional parathyroids [31–34]. However, in the
same tissues, Muller-Hocker did not observe a decrease in the
mitochondrial transcription factor TFAM, nor in the gamma polymerase
(POLG), whereas mtDNA content was higher in oncocytic cells [34],
suggesting a compensatory effect due to a complex IV deﬁciency [33].
With respect to the decrease in oxygen tension observed during
the initial exponential growth of the tumor, it has been proposed that
the respiratory chain produces increased levels of reactive oxygenspecies (ROS) when cells experience hypoxia [35]. Whether these ROS
may represent the trigger for a retrograde signalling to the nucleus
underlying an early-stage oncocytic modiﬁcation, either through the
induction of a mitochondrial DNA damage or through a proliferative
stimulus, remains yet to be demonstrated. More likely appears the
involvement of nitric oxide (NO) in contributing to oncocytic change.
NO levels seem to increase as oxygen tension decreases in a pH-
dependent fashion since catabolism by the cytochrome c oxidase may
not occur when the enzyme is prevalently in a reduced state (for a
review see [36]). Since NO has been implicated in the regulation of
mitochondrial biogenesis [37], this gas may constitute a stimulus for
the mitochondrial modiﬁcations typical of oncocytic tumors. Caution
is however warranted, since it seems unlikely that in shortage of
oxygen, when the respiratory chain may not be utilized for ATP
production, cells may be predisposed to activate mitochondrial
biogenesis pathways.
3. Does the mitochondrial energetic impairment in oncocytomas
trigger the compensatory mechanism?
Until 2003 the compensatory effect in oncocytic tumors was
describedasapredominant feature but the trigger for suchamechanism
was not investigated. On the track of the embryonal suggestion by
Muller-Hocker that a respiratory deﬁciency may underlie oncocytic
transformation in normal parathyroid cells, likely in correlation with an
agingprocess [33], the groupofGodinot demonstrated that deﬁciency of
complex I in renal oncocytomas might be the early event causing the
increased mitochondrial biogenesis, attempting to compensate a
respiratory dysfunction [38]. In addition they reported complex I
enzyme activity to be moderately decreased in the proximity of the
oncocytic tumor, when compared with normal tissue adjacent to the
othermore aggressive renal tumors analyzed. This led them to speculate
that oncocytomasmaybe the result of two consecutive alterationsof the
mitochondrial respiratory chain [38]. Following these in vivo studies on
renal oncocytoma our group fully characterized the bioenergetic
competence of the only existing cellmodel for thyroid oncocytic cancer,
namely the XTC.UC1 cell line [39]. We reported a mitochondrial
energetic impairment due to a decrease in both complex I and III
activity, and, in parallel, an increased level of most respiratory chain
complexes subunits, whereas complex I NDUFA9 and mitochondria-
coded ND6 were speciﬁcally reduced. Moreover, we observed that
complex I mitochondria-coded ND1 subunit was absent [40]. In the
same paper we also demonstrated that the energetic dysfunction was
transferred along with mitochondria in a trans-mitochondrial cell
hybrid (cybrid) model and hence concluded that the cause for this
dysfunction resided within these organelles. A similar decrease in
complex I subunits content was reported by our group in a rare case of
nasopharynx oncocytoma, along with a mtDNA copy number increase
[41]. Noticeably, a decrease in the activity of complexes I and IV was
recently reported in vivo in a peculiar case of Warthin tumor, thus
extending the feature of a bioenergetic defect to a plethora of oncocytic
tumor types [42]. All the data collected so far point at a dysfunction of at
least respiratory complex I as the main trigger for the subsequent
increase in other mitochondrial proteins and, hence, for the compen-
satory effect in oncocytic cells.
4. Is there a genetic signature of oncocytic tumors?—Familial forms
and genetic predisposition
Cancer is a genetically determined disease. Oncocytic neoplasms
are no exception, although no oncogene is known to date to be
univocally responsible for oncocytic tumor genesis. The occurrence of
oncocytic cancer in familial forms has been extensively reported,
although exclusively in the thyroid and in kidney. In thyroid, a locus
predisposing to a familial form of thyroid carcinoma with cell
oxyphilia (TCO) has been mapped on chromosome 19p13, although
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have been recently discussed by our group elsewhere [43] and are not
within the aims of the present review. It has to be underlined that
oncocytic thyroid tumors also occur within the frame of genetic
syndromes whose causative genes are well characterized, such as
Cowden syndrome, that derives from PTEN inactivation [44]. Overall,
two genes encoding mitochondrial proteins have been proposed as
candidates for thyroid oncocytic tumorigenesis, namely the mito-
chondrial inner membrane translocase TIMM44 and the complex I
assembly subunit GRIM-19 (NDUFA13). Both genes were proposed
independently by our group [45] and by Maximo et al. [46]
respectively, on the basis of their physical position within the TCO
locus that had been previously genetically mapped by our group on
chromosome 19 [47]. Although the position of GRIM-19 was
subsequently corrected (19p rather than 19q), Maximo et al. reported
occurrence of somatic mutations in GRIM-19 in three out of 20
sporadic, but not in the 6 cases of familial thyroid oncocytic tumors
analyzed, thus ruling out a role for this gene in familial predisposition
to TCO [46]. TIMM44 remains a potential candidate as germ-line
mutations were shown to segregate with the TCO phenotype,
although functional studies of such mutations did not indicate a
clear deranging effect on the protein function [45]. These studies
suggest that nuclear genes coding for mitochondrial proteins should
not be overlooked in the search for candidate genes predisposing to
oncocytic tumorigenesis, although mutations in such genes may
simply be responsible for the mitochondrial hyperplasia, rather than
cell transformation. Caution is therefore warranted to distinguish
genes implicated in oncocytic transformation from those predisposing
to familial cancers.
Renal oncocytomas have been found at higher frequency in family
pedigrees and this familial oncocytosis has been associated with Birt–
Hogg–Dubé syndrome (BHD), a rare autosomal dominant disorder
ﬁrst described in 1977 [48]. The syndrome affects the skin inducing
benign proliferation of the hair follicles (ﬁbrofolliculomas) at 20–
30 years of age. It also increases the risk of certain types of neoplasia,
particularly kidney tumors. The genetic alteration for BHD has been
mapped to chromosome 17p11.2 and the gene which is likely
responsible for BHD has been characterized [49]. This gene codes for
the protein folliculin (FLCN) that seems to act as tumor suppressor.
Although the function of FLCN is still unknown, it has been suggested
that this protein might have a role in energy/nutrient-sensing
signalling pathways [50]. Different types of renal tumors were noted
in patients affected with the BHD syndrome including bilateral
oncocytic neoplasms. Microscopic oncocytosis has been found in
many patients and these lesions may be precursors of oncocytic
tumors [51]. Noticeably, more than one case of parotid oncocytoma in
association with BHD syndrome has been documented [52].
Familiarity of oncocytic tumors suggests that a common genetic
event, at least underlying thyroid, kidney and parotid oncocytic
cancer, may be the main determinant of the disease, regardless of the
organ in which it occurs. Moreover, even in sporadic renal
oncocytoma, unlike in thyroid, a fairly large number of cases may be
grouped according to speciﬁc chromosomal aberrations. The ﬁrst
subgroup of oncocytomas shows allelic loss at chromosome arm 1p
along with loss of material from one sex chromosome (Y in men, X in
women), a reason why the involvement of genes in the pseudo-
autosomal region was suggested [53]. The second subgroup of renal
oncocytomas shows a characteristic chromosomal anomaly in the
11q12–13 region and several case reports suggested that this region is
prone to rearrangements in renal oncocytoma [54,55]. All these data
point to the involvement of speciﬁc oncogenes whose identity to date
remains unknown. Because of the peculiar mitochondrial hyperplasia,
though, it does not seem unlikely that such oncogenes may derange,
among others, mitochondrial biogenesis or metabolism triggering the
compensatory effect discussed above. It is noteworthy that several
genes for mitochondrial proteins map on 11q13 [56–58], hence a rolefor mitochondrial proteins has been hypothesized [59]. This is further
supported by studies on gene expression in renal tumors [28] in
which over-expression of mitochondrial proteins encoding genes
such as nicotinamide nucleotide transhydrogenase, fumarate hydra-
tase (FH) and solute carrier family 25 members 4 and 5 was
demonstrated in oncocytoma and clear-cell renal cell carcinoma
along with over-expression of the stem cell factor receptor KIT which
is implicated in several neoplasms [28]. Both Higgins et al. and Fuzesi
et al. suggested that a linkmay exist between defects inmitochondrial
proteins and the characteristic oncocytic phenotype of mitochondrial
hyperplasia [28,54], although mutations in succinate dehydrogenase
subunit B (SDHB), a gene coding for a subunit of complex II of the
mitochondrial respiratory chain, were not found in 4 samples of
oncocytoma analyzed by Morris et al. [60].
The importance of speciﬁc nuclear genes in causing the common
oncocytic phenotype of certain syndrome-associated neoplasms
should not be underestimated. Candidates for further investigation
may be suggested by gene expression studies. For instance, over-
expression of both nuclear respiratory factor 1 (NRF1) and nitric oxide
synthase 3 (NOS3) in oncocytic thyroid cancer indicates a role for
these genes in determining, or at least contributing to, oncocytic
transformation, as they may be responsible for regulating the
mitochondrial biogenesis so obviously deranged in oncocytic tumors
[27]. Nitric oxide in fact has been shown to regulate biogenesis by
inducing PGC1α [61]. Similarly, over-expression of PRC [26] as a
consequence of nutrients and growth factors abundance (for a review
see [62]) may provide clues on the nuclear mechanisms responsible
for a common oncocytic transformation among different tumors. The
involvement of PRC may in fact explain the delay between tumor
genesis and the appearance of the oncocytic phenotype, which would
hence occur once the tumor becomes well supplied through
neoangiogenesis. Noticeably, over-expression of PRC was also
observed by our group in parotid oncocytoma and Warthin tumors
(unpublished results). Since PRC appears to be a ubiquitous regulator,
his role in determining oncocytic transformation will likely gain
importance.
5. Where mitochondrial genetics ﬁt within oncocytic transformation
5.1. The mitochondrial DNA
The most striking biological feature of oncocytic tumors is
undoubtedly their marked mitochondrial hyperplasia. Human mito-
chondria possess a multicopy, circular chromosome encoding 13
essential polypeptides which become assembled within four of the
ﬁve oxidative phosphorylation complexes. The physiological poly-
ploidy of the mtDNA gives rise to a peculiar pattern of inheritance,
regulated by the phenomena of homo- and heteroplasmy, the latter
being the coexistence in a cell, or a tissue, of two or more different
mitochondrial genotypes. Because of this phenomenon, a single copy
of a mutated mitochondrial chromosome may be selected against or
shift to increase the mutation load until detrimental effects take over
to generate a pathological phenotype. The threshold level may vary
according to the mutation type and it has been shown in neurological
diseases that the penetrance or the severity of a condition may
depend on the level of heteroplasmy of the mutation [63,64]. Features
that render the mtDNA more prone to the accumulation of mutations
than the nuclear DNA, include (i) the proximity to reactive oxygen
species production sites, (ii) a less efﬁcient DNA repairing system, (iii)
the lack of protective histones, (iv) the highly compact structure
which lacks buffering sequences such as introns. Besides coding
sequences, the mtDNA contains a regulatory region called the
displacement loop (d-loop), which presides to both transcription
and replication upon binding of a set of nuclear encoded mitochon-
drial speciﬁc proteins such as DNA-polymerase gamma (POLG),
mitochondrial transcription factor (TFAM) and the helicase Twinkle.
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identiﬁed along with hypervariable segments. A long list of variants
and mutations is to date available for the d-loop region in public
databases, although functional studies to deﬁne the effects of such
genetic changes are very scarce in the literature. The d-loop is
essential for producing the polycistron that is then transformed into
separate transcripts, upon excision of the tRNA sequences inter-
spersed within the mtDNA [65]. Hence, mutations impairing func-
tional regions of the d-loop may determine a more severe pathologic
phenotype than those within coding segments, since they may affect
transcription of all mitochondria-coded genes. The same paucity of
mechanistic studies also concerns the role of the latter type of
mutations in tumor genesis or development.
5.2. MtDNA alterations in oncocytic tumors
The genetic cause of the mitochondrial energetic impairment
reported in oncocytic tumors is a recent discovery and resides,
unsurprisingly, within the mitochondrial genome. The presence of
aberrant mtDNA in oncocytic cancer was at ﬁrst investigated by
restriction pattern analysis and PCR, leading initially to the wrong
conclusion that no alterations of the mitochondrial genome were
present in oncocytic thyroid tumors. Nonetheless, later on, Tallini et
al. detected the common deletion, a frequent alteration of the
mitochondrial genome reported in cancer and aging and comprising
4977 bp, in a panel of thyroid oncocytic tumors. The same alteration
was also found, though, in perilesional thyroid tissue [66]. Maximo et
al. conﬁrmed the occurrence of the common deletion in thyroid
cancer, although not in association with the oncocytic features of the
neoplasm, and occurring as a somatic mutation at variance with the
study by Tallini et al. [67,68]. It has to be underlined that a biological
signiﬁcance of this clearly pathogenic mutation may not be evident if
one considers that 16%was the highest heteroplasmy level detected in
samples [67]. It is plausible to reckon that the threshold should be
higher even for such a largemitochondrial chromosomal aberration in
order for a defective phenotype to appear, as it is shown for other
mutations [69].
As sequencing of the entire mtDNA has become a more feasible
approach allowing detection of even low heteroplasmy levels, an
increasingnumber ofmtDNAmutationshas beendescribed inoncocytic
tumors. Maximo et al. reported a high prevalence of somatic
mitochondrial variants in 79 thyroid cancer samples, 43 of which
presented oncocytic features [70]. Direct automated sequencing was
used to screen up to 70% of the mitochondrial genome, covering
however only protein-coding segments. It is hence plausible to think
that the actual number of somatic variants might have been under-
estimated. D-loop instability was reported to occur in many of the
oncocytic samples, with the homopolymeric C and CA stretches varying
in length with respect to the tumor-adjacent normal tissue, especially
around positions 303 and 514 [70]. However, these repetitive stretches
are hot-spots for DNA fragment length variation, which represents a
common polymorphism of still undeciphered biological signiﬁcance
[71]. Few of the 57 somatic changes reported by Maximo et al. were
clearly damaging, being frameshift or nonsense changes in coding
sequences and good candidates for the respiratory defects observed in
oncocytic tumors, opening the way to subsequent studies by our and
other groups. Thepathogenic potential of non-disruptivemutationswas
not addressed, norwas theheteroplasmic status, a necessary issuewhen
dealing with heterogeneous tumors such as in the thyroid. In the same
study, the authors underline that no signiﬁcant difference was found
between the occurrence of mtDNA variants in oncocytic and non-
oncocytic tumors, except for those occurring in the ATP6 complex V
gene. Such changes were hence suggested to be hallmarks of the
oncocytic transformation [70], although in silico prediction of the
pathogenic potential of these mutations fails to provide a striking
indication of their role in the energetic impairment.On the basis of our observation of a speciﬁc decrease in complex I
subunits expression and activity in the only existing thyroid oncocytic
tumor cell model, our group demonstrated that the mitochondrial
energetic failure was dependent on two mtDNA mutations affecting
complexes I and III of the respiratory chain [37]. One of these
mutations was a single base pair homoplasmic insertion in a C-
homopolymer in the ND1 complex I gene, causing a premature stop
codon, which explained the absence of the protein. The second was a
non-conservative heteroplasmic missense mutation in the CYTB
complex III gene. These two mutations were sufﬁcient to explain
the defective ATP synthesis already reported in the same cell line
[23,24]. We hence demonstrated that clearly pathogenic, truncating
mutations impairing complex I were univocal genetic markers of
thyroid oncocytic tumors, upon analysis of a panel of 45 samples
against 52 non-oncocytic control tumors. In the same study we ruled
out an age-dependent accumulation of such somatic mutations. The
same lack of correlation was hence reported with respect to tumor
aggressive/malignant behaviour [17]. Even more strikingly, 100% of
kidney oncocytomas, analyzed in a study by Simonnet's group in
collaboration with ours, presented the same type of disruptive
mutations, substantially explaining the corresponding defective
respiration paralleled by an increase in citrate synthase activity [72].
Independent observations byMayr et al. conﬁrmed the sameﬁndings in
renal oncocytoma [73] and, later on, in thyroid oncocytic tumors [74].
The same high frequency of disruptive mutations was reported also in
parathyroid oncocytic neoplasms [75]. Recently our analysis was
extended to a panel of oncocytic tumors of the pituitary and salivary
glands and the signiﬁcant association of a high frequency of pathogenic
mtDNAmutations with the oncocytic phenotype was conﬁrmed, ruling
out a tissue-speciﬁcity for mutations occurrence [42]. Most mutations
reported so far by our group were both disruptive and homoplasmic,
indicating that a shift towards a full mutant load (100%) in cancer cells
occurs andmay not be due simply to random genetic drift, sustained by
transformed cells despite the apparent detrimental biochemical effects.
To date 152 entire mtDNA sequences have been obtained from
oncocytic tumor samples so that some statistical analysis is possible
(Table 1). In order to assess whether a hotspot mitochondrial gene
does exist, we have collected all the somatic (cancer speciﬁc) variants
reported in the ﬁve papers where at least all the coding mtDNA
sequences have been analyzed (Table 1). Assuming that all mtDNA
regions should be equally susceptible to mutations, we have then
calculated the ratio between the frequency of reported and expected
mutations per mitochondrial gene after normalizing on the gene
length. Fig. 1A clearly shows that ND1 is indeed a hotspot for somatic
changes with a ratio of over 3, meaning that mutations occur in this
gene at a frequency more than three times higher than expected on
the basis of the gene length. Similarly, although less strikingly, ND4,
ND5 and ATP6 also display a tendency to accumulate somatic changes
(Fig. 1A). On the contrary, COI and ATP8 appear to be more protected
from mutational events. We have further extended this type of
analysis by taking into consideration only those changes for which a
high pathogenic potential could be predicted. Overall, 101 changes
were predicted to be pathogenic (i.e. were predicted to be possibly or
probably damaging by PolyPhen). In this frame, ND1 still had a ratio
above 3, indicating that this subunit may more frequently face a
mutational damage. Similarly, ND3, ND4,ND4L andND5 also displayed
a ratio greater than 1.5. Interestingly, all complex IV and V genes (COI,
COII and COIII, ATP6 and ATP8) seemed to be preserved from the
occurrence of damaging mutations (Fig. 1B). Several hypotheses may
be formulated to speculate on these differences in mitochondrial
susceptibility to damaging mutations. First, it has been shown that
different regions of the mammalian mtDNA display a different degree
of conservation, with ND1, ND3, ND4, ND4L and ND5 being less
evolutionary conserved than COI, COII and COIII [76]. In this context
the mentioned ND subunits may better sustain the occurrence of non-
conservative missense variants. Second, a different threshold for a
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respect to ND1. In fact, whereas for COI 40% of mutated DNA is
sufﬁcient to generate a defective respiration [69], over 90% of mutated
ND1 copies are necessary to obtain the same effect [42,69]. Finally, it is
interesting to note that ND4 and ND5 are the richest in homopoly-
meric stretches (here arbitrarily deﬁned as polyA, C, G and T longer or
equal to 5 bases), with 11 and 12 stretches respectively. ND2, ND1 and
ND6 are also rich in homopolymers (9, 7 and 7, respectively).
Instability of homopolymeric stretches is suspected to predispose to
accumulation of somatic mutations, similarly to what is observed in
the polyC stretches of the d-loop region, where somatic variations in
the length of the homopolymer have been extensively reported in
cancer and particularly in thyroid oncocytic tumors [77]. Abundance
of such unstable regions is in agreement with the higher susceptibility
of ND subunits to truncating mutations, which very often occur in
homopolymers [17,42,72].
5.3. MtDNA mutations as a cause or a consequence of the oncocytic
phenotype—The egg or the chicken metaphor
Oncocytic transformation has been strongly associated with a
compensatory effect due to a mitochondrial dysfunction leading to an
increase of mitochondrial mass. Nonetheless where and how mtDNA
mutations fall within this process is yet unclear and scarcely
investigated. It is worth noting that the mtDNA mutations underlying
the oncocytic phenotype may not be the primary hit in tumorigenesis,
as previously suggested [17]. We reported a peculiar case of a patient
that presented three tumor nodules, only one of which displayed an
oncocytic phenotype and, along with it, a nonsense mutation in a
complex I subunit. The exclusive occurrence of the mutation in the
oncocytic nodule led us to hypothesize that this should be a secondaryTable 1
Somatic and potentially pathogenic changes reported in oncocytic tumors.
Gene
(length, bp)
Gasparre
et al. [17]
Gasparre
et al. [72]
Porcelli
et al. [42]
Maximo
et al. [70]
Costa-Guda
et al. [75]
Total
(A) Somatic changes reported in oncocytic tumors
ND1 (955) 10 5 6 1 3 25
CYTB (1140) 5 1 1 2 0 9
ND6 (524) 0 1 0 2 0 3
ND4 (1377) 7 1 8 2 1 19
ND5 (1811) 7 4 10 2 3 26
ND4L (296) 1 0 0 1 1 3
ND3 (345) 0 0 1 3 0 4
COIII (783) 0 0 0 5 0 5
ATP6 (680) 3 0 0 7 0 10
ATP8 (206) 0 0 0 0 0 0
COII (683) 0 0 0 5 0 5
COI (1541) 0 1 2 2 2 7
ND2 (1041) 4 0 3 2 1 10
(B) Potentially pathogenic changes reported in oncocytic tumors
ND1 (955) 10 5 6 0 3 24
CYTB (1140) 5 1 1 2 0 9
ND6 (524) 0 1 0 2 0 3
ND4 (1377) 7 1 8 0 1 17
ND5 (1811) 7 4 10 0 2 23
ND4L (296) 1 0 0 1 1 3
ND3 (345) 0 0 1 3 0 4
COIII (783) 0 0 0 2 0 2
ATP6 (680) 3 0 0 0 0 3
ATP8 (206) 0 0 0 0 0 0
COII (683) 0 0 0 2 0 2
COI (1541) 0 1 2 0 0 3
ND2 (1041) 4 0 3 0 1 8
The table reports the number of somatic (tumor-speciﬁc; Table 1A) and tumor-speciﬁc
potentially pathogenic changes (Table 1B) occurring in protein-coding mtDNA genes.
Values have been extrapolated from the ﬁve papers in which at least the entire protein-
coding mtDNA sequence was obtained. All missense changes reported have been
subjected to in silico prediction of pathogenic potential by PolyPhen and probably/
possibly pathogenic changes only have been included in Table 1B.
Fig. 1. Frequency ratio ofmtDNAmutations occurring in protein-coding genes. (A) Somatic
changes. (B) Potentially pathogenic changes as predicted by PolyPhen. Different shades of
colour indicate different susceptibility tomutations occurrence. Scale value from 0 to above
3 was calculated as ratio of mutation frequencies (obtained dividing the single values
reported in Tab.1A and B per gene by the overall number of mutations) over the percentage
of mtDNA occupied by the gene. Genes with values below 0.7 have been arbitrarily deﬁned
as “preserved from theoccurrence ofmutations”, whereas geneswith values above 1.5 have
been deﬁned as “mutational hotspots”.event in tumorigenesis responsible for the mitochondrial hyperplasia
and hence for the oncocytic transformation [17]. To further support
this hypothesis, we described a disruptive frameshift mtDNA
mutation affecting the ND5 subunit of complex I present in
homoplasmy in a nasopharyngeal oncocytic tumor. This mutation
was inherited at low degree of heteroplasmy through the germline in
the patient family but became homoplasmic in the tumor of the
patient only. The mutation was hence present in the patient tissues
prior to the tumor occurrence and, although it might be predisposing
to oncocytic transformation through a shift to homoplasmy, it is
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in different oncocytic areas of the same tumor of the reported case, a
damaging homoplasmic ND1 mutation was described where the ND5
germline mutation was still heteroplasmic, suggesting a common
nuclear tumorigenic hit and at least two subsequent and independent
mitochondrial mutations [41].
In this context, oncocytic transformation ought to be conceptually
and temporally separated from oncogenic transformation, which
should occur ﬁrst. The question remains open of whether mtDNA
mutations actively contribute to the oncocytic transformation or
occur and become selected in the context of a deregulated
mitochondrial biogenesis and hyperplasia. The ﬁrst hypothesis ﬁts
better with a compensatory process in which the mtDNA mutation is
the event causing the mitochondrial dysfunction that triggers a
retrograde signalling to the nucleus. The response to such signalling is
an increase in mitochondrial biogenesis in the attempt to rescue the
defective phenotype (Fig. 2A). It has been reported that nonsense
mtDNA mutations in ND5 and COI speciﬁcally trigger the up-
regulation of PGC1α/β and the over-expression of mitochondrial
proteins so that cell respiration is somehow rescued. Although this
was observed in a non-oncocytic tumor cell line, the authors
suggested a retrograde mechanism calcium-mediated at the basis of
the observed increase in biogenesis. Nevertheless the occurrence of an
oncocytic-like phenotype in these cells was not investigated at all
[78]. According to the second hypothesis, mitochondrial biogenesis
may be triggered in response to an increased inﬂux of nutrients or
growth factors (as discussed in paragraph 4), or by the activation of
the same oncogene responsible for the primary cell transformation,
such as, for instance, H-RAS. Such a mechanism has been demon-
strated in primary ﬁbroblasts infected with this oncogene, upon
which up-regulation of several genes involved in mitochondrial
biogenesis occurred. Interestingly, up-regulation of biogenesis
appears to be dependent on genes involved in the DNA damage
repair and regulating oncogene-induced senescence such as TP53 and
Rb, although themechanistic links are still lacking [79]. In this context,
the oncogene-dependent biogenesis may facilitate the occurrence and
accumulation of mtDNA mutations (Fig. 2B).
The relationship between oncocytic transformation and the
mitochondrial involvement in oncogene-induced senescence war-
rants further investigation and will be decisive in placing the mtDNA
mutation within tumor progression.
6. Structural and functional consequences of mtDNAmutations on
oncocytic cancer cells
6.1. The impact of mtDNA mutations on respiratory complexes assembly
Altogether, all data collected thus far in oncocytic tumors point to
respiratory complex I as the major hotspot for the occurrence of
damaging mtDNA mutations. Once again the XTC.UC1 cell model of
oncocytic neoplasia has been very useful in clarifying the effects of the
homoplasmic truncating mtDNA mutations on the energetic function
and, in particular, on the respiratory complex content and assembly
[80]. In fact, the 3571insC ND1 mutation was shown to ablate ND1
content as well as to reduce the levels of other complex I subunits
such as the nuclear-coded NDUFA9 and the mitochondria-coded ND6.
No other complexes subunits appeared to be affected among those
analyzed [40]. On these bases, our group showed that the complex I
subunits are lost in vivo in oncocytic tumors exclusively in the
presence of homoplasmic truncating ND mutations [41]. Immunohis-
tochemical staining for the ND6 subunit has proven to be a useful tool
to identify at least partial complex I disassembly so that it may easily
be utilized with a predictive potential of the occurrence of disruptive
mtDNAmutations. The peculiarity of ND6 is indeed that its expression
is inﬂuenced by that of other ND subunits, because of its pivotal role in
the ND-arm assembly [81]. Hofhaus and Attardi had in factdemonstrated that a disruptive mutation in the ND5 subunit was
associated with under-expression of ND6 [82]. In agreement with
these ﬁndings, we reported that nuclear-coded NDUFB6 subunit
showed a positive staining even in the absence of ND6. Although lack
of ND6 is strongly suggestive of a disassembly of the γ subcomplex of
the complex I hydrophobic arm, positive staining of NDUFB6 in vivo
does not provide indication on whether the proteins are synthesized
and retained in the cytosol or they are imported and assembledwithin
abortive β subcomplex of the complex I hydrophobic arm [83].
Interestingly, the hydrophilic λ-arm of complex I was also reported to
be lacking in oncocytic thyroid tumors upon occurrence of mtDNA
mutations. The same authors reported an increased staining of
subunits belonging to the other four complexes and the structural
protein porin [74]. Similar results were recently reported by our group
in a large panel of pituitary, head-and-neck, and thyroid oncocytic
tumors, in correlation with homoplasmic mtDNA truncating muta-
tions, where intense complex V staining strongly indicated the
oncocytic phenotype [42]. An example of a thyroid oncocytic tumor
in which lack of ND6 and NDUFB6 is evident, along with over-
expression of complex V subunit ATP5B, is reported in Fig. 3. The
alteration of mitochondria cristae, likely following respiratory com-
plexes disruption, is also shown.
6.2. Do ROS have a role in oncocytic tumorigenesis?
The occurrence of mtDNA mutations implying an incomplete or
partial assembly of complex I raises the question of whether this may
contribute to ROS generation. Zimmermann et al. speculated that the
observed lack of complex I staining in oncocytic thyroid may have a
role in tumor formation through the increase in ROS production and,
simultaneously, a downstream inhibition of pro-apoptotic pathways,
although the nuclear-coded complex I subunits called into play are
not apoptotic effectors, but rather caspases targets [74]. Lack of data
on the role of ROS in oncocytic tumors is mainly due to the fact that
studies on tumor biopsies are not feasible and that cell models for in
vitro studies are very scarce. Investigation of ROS production in the
XTC.UC1 cells showed that the different degree of heteroplasmy of the
3571insC ND1 mutation does not inﬂuence ROS amounts. This was
explained with a differential expression of ROS detoxifying enzymes
such as manganese superoxide dismutase and catalase in presence/
absence of complex I [42]. Similarly, peroxiredoxin I, an oxygen
peroxide scavenging enzyme, was shown to be overexpressed in
oncocytic tumors of the salivary glands, which led the authors to
suggest that detoxifying mechanisms may be up-regulated in these
neoplasms likely carrying mitochondrial dysfunctions and electrons
leakage [84].
Nonetheless, further studies are warranted to dissect the role of
ROS in oncocytic tumors in vivo, where most of the mutations
reported are indeed homoplasmic and complex I appears to be
disassembled, to understand whether ROS may inﬂuence the
proliferative potential and the accumulation of mutations in these
tumors.
6.3. Apoptosis in oncocytic tumors
It is widely accepted that the growth advantage in tumors may
derive from increased survival due to prevention of apoptosis. The
intrinsic pathway of apoptotic cell death is also called the mitochon-
drial pathway, owing to the essential role played by these organelles.
In fact, at the level of the mitochondrial outer membrane, interaction
among anti-apoptotic and pro-apoptotic proteins of the Bcl-2 family
can occur, thus determining the cell fate. Furthermore, some pro-
apoptotic proteins (cytochrome c, AIF, Smac/DIABLO, OMI/Htr2A,
endonuclease G, etc.) are sequestered within the intermembrane
space, from where they can be released into the cytosol following
permeabilization of the outer membrane. Cytochrome c in the
Fig. 2. Scheme of the genesis of the oncocytic phenotype: the egg or the chicken metaphor. (A) MtDNA mutation (red lightning arrow) causes the mitochondrial dysfunction (shaded
mitochondrion) that triggers a retrograde signalling to the nucleus mediated by alterations of calcium homeostasis. The response to such signal is the up-regulation of PGC1α/β, which in
turn triggers activation of downstream effectors (as NRF, TFAMand POLG) leading tomitochondrial biogenesiswith increase inmtDNA copynumber in the attempt to rescue the defective
energetic phenotype. In this context accumulation of mutations may occur, in a feed-forward loop that would further stimulate the retrograde signalling. (B) A nuclear (pre)-oncogenic
stimulus triggers the DNA-repair response pathways such as those mediated by p53 and Rb, leading to the activation of mitochondrial biogenesis regulators and effectors through still
unknownmechanisms. The increase inmtDNA copy number subsequent to PGC1 up-regulationmay then determine the occurrence of the homoplasmic shift ofmtDNAmutations,which
in turn may contribute to trigger a retrograde signalling and accumulation of nuclear damage, i.e. through an increased oxidative stress.
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[85], whereas the other proteins are differently involved in promotion
of other types of cell death mechanisms (for a review see [86]). Owing
to these ﬁndings, it has been hypothesized that mtDNA mutations
impairing mitochondrial energetic function may protect cells fromFig. 3. Impact of mtDNAmutations on respiratory complexes assembly. Representative electr
left panel, ultrastructural features of mitochondria in an oncocytic tumor cell, displaying th
upper right panel, staining for complex V subunit ATP5B marks the oncocytic phenotype. N
ND6 complex I subunit is apparent in the more intense complex V stained, oncocytic part of tapoptosis, thus promoting growth advantage. In this regard, two
different homoplasmic pathogenic ATP6 mutations were previously
reported to lower the frequency of apoptosis both in cybrid cells and
in tumors derived from cybrid transplantation [87]. Furthermore, a
subsequent comparison of resistance to oxidative stress-inducedonmicroscopy and IHC images of an oncocytic hyperplastic thyroid nodule. In the upper
e dramatic alteration of the cristae organization (image courtesy of Dr. C. Betts). In the
egative staining for nuclear-coded NDUFB6 complex I subunit and mitochondria-coded
he nodule (upper side of NDUFB6 and ND6 panels) (Images courtesy of Dr. C. Ceccarelli).
Fig. 4. The blind alley of oncocytic tumors: a non-exit strategy? (A) A mtDNA mutation impairing complex I function but not its assembly may still allow and/or increase NADH
consumption, keeping a low NADH/NAD+ ratio and a consequent low α-ketoglutarate (α-KG)/succinate (SA) ratio. This in turn may not prevent HIF1α stabilization under hypoxic
conditions, allowing the up-regulation of glycolytic and pro-tumorigenic genes (i.e. GLUT1, LDHA and VEGF), ﬁnally permitting the metabolic adaptation of cells and hence tumor
progression (exit door). This would occur despite lack of mitochondrial respiration due to the mtDNA mutation (Warburg effect). (B) A mtDNA mutation disassembling complex I,
such as those typical of the oncocytic phenotype, may not allow NADH consumption, shifting the NADH/NAD+ ratio towards NADH and consequent α-ketoglutarate (α-KG)
accumulation. This Krebs cycle alterationmay induce activation of prolyl-hydroxylase and HIF1α degradation even in low oxygen tension conditions, preventing the up-regulation of
glycolysis needed to compensate for the defective mitochondrial respiration and leading the tumor into a blind alley (no access sign) without a way out to metabolic adaptation.
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apoptosis was indeed more pronounced in heteroplasmic than in
homoplasmic cells. This result was explained by the very limited
production of ATP by cells with homoplasmic ND5 mutation, that
would compromise cytochrome c-dependent caspase 9 activation
[88]. Whether mtDNA mutations prevent apoptosis also in oncocytic
tumors is still poorly deﬁned. So far, a microarray analysis showed
signiﬁcant down-regulation of caspase 3 expression in thyroid
oncocytic tumors, indicating a mechanism for inhibition of cell
death [89]. Once again studies in progress with the XTC.UC1 cell
model will provide useful information on this topic.
6.4. Consequences of mtDNA mutations on Krebs cycle and beyond
In the recent past, several observations have linked respiratory
complexes dysfunctions to alteration of upstream mitochondrial
metabolism, i.e. the Krebs cycle, in cancer. The best example is
given by hereditary paragangliomas, leiomyomas and renal carcino-
mas in which an aetiological role for complex II mutations has been
demonstrated. In fact, mutations in the B, C and D subunits of SDH
have been shown to lead to accumulation of the Krebs metabolite
succinate at the expenses of α-ketoglutarate. Similarly, mutations in
FH lead to accumulation of fumarate, slowing down the cycle [90,91].
These hereditary tumors are characterized by a condition of chronic
pseudohypoxia. In fact the accumulation of Krebs cycle metabolites
succinate and fumarate contributes to the inhibition of prolyl-
hydroxylases (PHD), key activators of the hypoxia inducible factor-
1α (HIF1α) degradation [92]. This factor has been long known to be a
critical player in mediating the metabolic adaptation needed by
cancer cell to progress from a benign to a malignant state [93].
The complex I dysfunction described in oncocytic tumors raises
the question of whether a parallel may exist between these neoplasmsand SDH/FH mutated cancers. To shed light on this issue we recently
attempted to deﬁne the levels of HIF1α-regulating Krebs cycle
metabolites in the XTC.UC1 cells bearing the homoplasmic truncating
ND1mutation.We demonstrated that the ratio between succinate and
α-ketoglutarate is opposite to what reported in SDH and FH mutated
tumors, with increase of α-ketoglutarate at the expenses of succinate
[42]. It is likely that the absence of a functional complex I in these cells
leads to accumulation of NADH, the main substrate of complex I.
Previous inhibitor afﬁnity studies in mitochondria harboring different
mtDNA mutations in complex I have clearly demonstrated that the
hydrophobic portion of the ubiquinone binding site involves ND1,
ND5, and ND6 subunits [94–96]. It is therefore likely that in the
context of oncocytic transformation, ubiquinone may not act as
acceptor for NADH-derived electrons. The consequent NADH accu-
mulation may, in turn, inhibit α-ketoglutarate dehydrogenase and
prevent succinate production with a consequent α-ketoglutarate
increase. Since α-ketoglutarate is the main feeding reagent of PHD,
HIF1α should undergo a chronic destabilization, even in the tumor
hypoxic environment. We have indeed shown this to be the case in
oncocytic tumors harboring homoplasmic disruptive mtDNA muta-
tions causing disassembly of complex I [42].
7. The blind alley of oncocytic cells: A strategy lesson on
tumor development?
These data raise the issue of how oncocytic cells can survive and
proliferate in the adverse tumor microenvironment, having a
deranged respiratory metabolism and being unable to stabilize
HIF1α, which powerfully regulates the expression of glycolytic
genes such as the glucose transporter GLUT1 [93]. HIF1α is also the
main inducer of the vascular endothelial growth factor (VEGF), a key
player regulating the generation of novel vasculature in the hypoxic
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oncocytic tumors displaying HIF1α destabilization do not present
features of neovascularization. Although HIF1α is expected to be
stabilized in central tumor areas lacking vessels, thismay be explained
by the deregulation of VEGF. This observation led us to propose that
HIF1α destabilization in oncocytic cells should be an event occurring
after the homoplasmic shift of the mtDNA mutation and before
neovascularization in tumor progression [42]. This consideration is in
agreement with the observation that the large majority of oncocytic
tumors harboring mtDNA mutations are indeed benign, non-
aggressive and low proliferating lesions [1,17,42]. The functional
correlation between homoplasmy of mtDNA mutations and a benign
behavior of oncocytic tumors is supported by similar ﬁndings in non-
oncocytic cancermodels, such as those recently described by Park et al.
These authors reported a lower tumorigenic potential of a homo-
plasmic truncating ND5 mutation with respect to the same mutation
in heteroplasmy [88]. Their study comes in a context where a
positive association between mtDNA mutations and tumorigenic,
pro-metastatic potential is investigated, also in terms of increase of
HIF1α stabilization [87,97], which is clearly not the case in oncocytic
tumors. When all these data on mtDNA mutations in tumor
development are gathered and critically analyzed, they indicate
that both the degree of heteroplasmy and the type of mutations
(missense versus truncating) must be carefully taken into account
since they may determine a completely opposite tumor phenotype.
Overall, the molecular marker of oncocytic tumors, namely the
homoplasmy of disassemblingmutations, drives the oncocytic cell in a
blind alley: the mitochondrial energetic impairment on one side and
the inability to compensate with an increased glycolytic metabolism,
along with the inability to induce neovascularization, should lead the
cell to proliferative arrest (Fig. 4). What speciﬁc molecular and
cellular pathways may be actively involved to regulate this inhibition
of growth is still an unexplored ﬁeld of research, which we are
currently investigating. Both the induction of senescence and
autophagy may represent a smart strategy for the cell to counteract
the deregulated tumor proliferation. These processes may be
synergistic with the homoplasmic shift of mtDNA mutations. The
demonstration of whether this derives from a random event or from a
controlled induction, through the activation of mitochondrial biogen-
esis mechanisms, represents the most exciting challenge in the
current research on the role of mitochondrial metabolism in oncocytic
tumors.
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